160 related articles for article (PubMed ID: 8757425)
1. Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection.
Frissen PH; Weverling GJ; Endert E; Jansen J; Sauerwein HP; Lange JM
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):482-8. PubMed ID: 8757425
[TBL] [Abstract][Full Text] [Related]
2. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
Godfried MH; van der Poll T; Mulder JW; Weverling GJ; Endert E; Lange JM; Sauerwein HP
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):531-9. PubMed ID: 8548332
[TBL] [Abstract][Full Text] [Related]
3. Increased concentrations of soluble tumor necrosis factor receptor 75 but not of soluble intercellular adhesion molecule-1 are associated with the decline of CD4+ lymphocytes in HIV infection.
Zangerle R; Fuchs D; Sarcletti M; Gallati H; Reibnegger G; Wachter H; Dierich MP; Möst J
Clin Immunol Immunopathol; 1994 Sep; 72(3):328-34. PubMed ID: 7914841
[TBL] [Abstract][Full Text] [Related]
4. Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group.
Fernández-Cruz E; Lang JM; Frissen J; Furner V; Châteauvert M; Boucher CA; Dowd P; Stevens J
AIDS; 1995 Sep; 9(9):1025-35. PubMed ID: 8527074
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor alpha and soluble tumor necrosis factor receptors in individuals with human immunodeficiency virus infection.
Zangerle R; Gallati H; Sarcletti M; Wachter H; Fuchs D
Immunol Lett; 1994 Jul; 41(2-3):229-34. PubMed ID: 8002043
[TBL] [Abstract][Full Text] [Related]
6. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection.
Mildvan D; Spritzler J; Grossberg SE; Fahey JL; Johnston DM; Schock BR; Kagan J
Clin Infect Dis; 2005 Mar; 40(6):853-8. PubMed ID: 15736019
[TBL] [Abstract][Full Text] [Related]
7. Serum HIV-1 RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1-infected individuals.
Zangerle R; Steinhuber S; Sarcletti M; Dierich MP; Wachter H; Fuchs D; Möst J
Int Arch Allergy Immunol; 1998 Jul; 116(3):228-39. PubMed ID: 9693271
[TBL] [Abstract][Full Text] [Related]
8. Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91-253 Study Team.
Krown SE; Aeppli D; Balfour HH
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Mar; 20(3):245-54. PubMed ID: 10077172
[TBL] [Abstract][Full Text] [Related]
9. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
Bartlett JA; Benoit SL; Johnson VA; Quinn JB; Sepulveda GE; Ehmann WC; Tsoukas C; Fallon MA; Self PL; Rubin M
Ann Intern Med; 1996 Aug; 125(3):161-72. PubMed ID: 8686973
[TBL] [Abstract][Full Text] [Related]
10. The effect of zidovudine treatment on serum neopterin and beta 2-microglobulin levels in mildly symptomatic, HIV type 1 seropositive individuals.
Bass HZ; Hardy WD; Mitsuyasu RT; Taylor JM; Wang YX; Fischl MA; Spector SA; Richman DD; Fahey JL
J Acquir Immune Defic Syndr (1988); 1992; 5(3):215-21. PubMed ID: 1346807
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of combined response markers among human immunodeficiency virus-infected persons: possible aid in the decision to change zidovudine monotherapy.
Graham NM; Park LP; Piantadosi S; Phair JP; Mellors J; Fahey JL; Saah AJ
Clin Infect Dis; 1995 Feb; 20(2):352-62. PubMed ID: 7742442
[TBL] [Abstract][Full Text] [Related]
12. Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clincal Trial Group 068.
Mildvan D; Bassiakos Y; Zucker ML; Hyslop N; Krown SE; Sacks HS; Zachary J; Paredes J; Fessel WJ; Rhame F; Kramer F; Fischl MA; Poiesz B; Wood K; Ruprecht RM; Kim J; Grossberg SE; Kasdan P; Bergé P; Marshak A; Pettinelli C
Antivir Ther; 1996 Apr; 1(2):77-88. PubMed ID: 11321183
[TBL] [Abstract][Full Text] [Related]
13. A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia.
Phanuphak P; Grayson ML; Sirivichayakul S; Suwanagool S; Ruxrungtham K; Hanvanich M; Ratanasuwan W; Ubolyam S; Hughes MD; Wanke CA; Hammer SM
Aust N Z J Med; 2000 Feb; 30(1):11-20. PubMed ID: 10800872
[TBL] [Abstract][Full Text] [Related]
14. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.
Jacobson MA; Bacchetti P; Kolokathis A; Chaisson RE; Szabo S; Polsky B; Valainis GT; Mildvan D; Abrams D; Wilber J
BMJ; 1991 Jan; 302(6768):73-8. PubMed ID: 1671651
[TBL] [Abstract][Full Text] [Related]
15. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity.
Stretcher BN; Pesce AJ; Frame PT; Greenberg KA; Stein DS
AIDS; 1994 Jun; 8(6):763-9. PubMed ID: 8086134
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
[TBL] [Abstract][Full Text] [Related]
17. Soluble receptors for tumour necrosis factor: a putative marker of disease progression in HIV infection.
Godfried MH; van der Poll T; Jansen J; Romijin JA; Schattenkerk JK; Endert E; van Deventer SJ; Sauerwein HP
AIDS; 1993 Jan; 7(1):33-6. PubMed ID: 8382926
[TBL] [Abstract][Full Text] [Related]
18. Elevated serum calprotectin levels in HIV-infected patients: the calprotectin response during ZDV treatment is associated with clinical events.
Müller F; Frøland SS; Aukrust P; Fagerhol MK
J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):931-9. PubMed ID: 7914232
[TBL] [Abstract][Full Text] [Related]
19. Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-2 infection.
Whittle H; Egboga A; Todd J; Corrah T; Wilkins A; Demba E; Morgan G; Rolfe M; Berry N; Tedder R
AIDS; 1992 Jul; 6(7):685-9. PubMed ID: 1354448
[TBL] [Abstract][Full Text] [Related]
20. The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin.
Merigan TC; Hirsch RL; Fisher AC; Meyerson LA; Goldstein G; Winters MA
AIDS; 1996 Feb; 10(2):159-65. PubMed ID: 8838703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
